A.S.P.E.N. Clinical Guidelines

Update on Parenteral Nutrition Ordering, Order Review, Compounding, Labeling and Dispensing!

Julianne Harcombe RPh, BCNSP



Disclosure Statement

I have no relevant financial relationships with commercial interests to disclose



Pharmacist Objectives

- Acknowledge the new 2014 A.S.P.E.N.
 Clinical Guideline on Parenteral Nutrition
 Ordering, Order Review, Compounding,
 Labeling, and Dispensing
- Recognize clinical advantages or disadvantages of commercially available premade multichambered Parenteral Nutrition formulations.



Pharmacist Objectives cont'd


- 3. Review the A.S.P.E.N. guidelines on Parenteral Nutrition Safety and discuss what pharmacists and pharmacy technicians can do together to improve best practice.
- Indicate the benefit of integrating Nutrition status into the Comprehensive Geriatric Assessment.



Technician Objectives

- Recognize the new 2014 A.S.P.E.N. Clinical Guidelines on Parenteral Nutrition, Compounding, Labeling, and Dispensing
- 2. Recognize advantages or disadvantages of premade Parenteral Nutrition formulations.
- 3. Review the A.S.P.E.N. guidelines on Parenteral Nutrition Safety and discuss how to improve best practice.
- Indicate the benefit of integrating Nutrition status into the Comprehensive Geriatric Assessment.





LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION

iety for Parenteral and Enteral Nutrition

20 A.S.P.E.N. Clinical Guidelines


- 2014 A.S.P.E.N. Clinical Guidelines: Support of Pediatric Patients with Intestinal Failure at Risk of Parenteral Nutrition – Associated Liver Disease
- 2. 2014 A.S.P.E.N. Clinical Guidelines: Parenteral Nutrition Ordering, Order Review, Compounding, Labeling, and Dispensing
- 3. 2013 A.S.P.E.N. Clinical Guidelines: Nutrition Support of Hospitalized Patients with Obesity
- 4.
- 5. 2013 A.S.P.E.N. Clinical Guidelines: Nutrition Support of Adult Patients with Hyperglycemia



A.S.P.E.N. Clinical Guidelines cont'd

- 17.2009 Adult Critical Care In collaboration with the Society of Critical Care Medicine (SCCM)
- 19.2004 Safe Practices for Parenteral Nutrition [Endorsed by the American Society of Health System Pharmacists (ASHP)]
- 20.2002 Guidelines A.S.P.E.N. Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients.





Question 1.

Does education of prescribers improve PN ordering?

Recommendation: We suggest providing education to healthcare professionals to improve PN ordering, thereby reducing errors.



Question 2. What is the maximum safe osmolarity of PN admixtures intended for peripheral vein administration?

Recommendation: We suggest that PN with an osmolarity of up to 900 mOsm/L can be safely infused peripherally.







Question 3. What are the appropriate calcium intake and calcium-phosphate ratios in PN for optimal neonatal bone mineralization?

Recommendation: We recommend an elemental calcium intake of 76 mg/kg per day for short-term PN in neonates.







Visit our patients on home PN

www.oley.org

www.mallorycyr.com



Question 4. What are the clinical advantages or disadvantages of commercially available premade ("premixed") multichambered PN formulations compared with compounded PN formulations?

Recommendation: We suggest that commercially available premade multichambered PN products be considered as an available option for patients alongside compounded (customized or standardized) PN formulations to best meet an organization's patient needs.





Question 5. What are the clinical (infection, catheter occlusion) advantages or disadvantages of 2-in-1 compared with 3-in-1 PN admixtures?

Recommendation: We suggest that there is no clinical difference in infectious complications between the two PN delivery systems; 3-in-1 formulations administered in the homecare setting may increase the risk for catheter occlusion and shorten catheter lifespan.

Question 6. What macronutrient dosing limits are expected to provide for the most stable 3-in-1 admixtures?

Recommendation: We recommend that total nutrient admixtures maintain final concentrations of amino acid ≥4%, monohydrated dextrose ≥10%, and injectable lipid emulsion ≥2% to be more likely to remain stable for up to 30 hours at room temperature (25°C) or for 9 days refrigerated (5°C) followed by 24 hours at room temperature.





Question 7. What are the most appropriate recommendations for optimizing calcium (gluconate) and (Na- or K-) phosphate compatibility in PN admixtures?

Recommendation: We cannot make a recommendation due to the multiple variations in amino acid concentrations, PN volume, pH, presence or absence of fat emulsion, and the amounts of other minerals (eg, magnesium). We suggest that published graphs for specific products provide adequate guidance; however, no evidence indicates that these formulations remain stable for >24–48 hours.



Question 8. What micronutrient contamination is present in parenteral stock solutions currently used to compound PN admixtures?

Recommendation: We suggest that, given the level of mineral contamination found in parenteral stock solutions used to compound PN admixtures, practitioners purchase products that accurately describe levels of contamination and also take that exposure into account when recommending or reviewing trace element dosing.

Question 9. Is it safe to use the PN admixture as a vehicle for non-nutrient medication delivery?

Recommendation: We recommend that non-nutrient medication be included in PN admixtures *only* when supported by (1) pharmaceutical data describing physicochemical compatibility and stability of (a) the additive medication and (b) the final preparation under conditions of typical use, and (2) clinical data confirming the expected therapeutic actions of the medication.



Question 10. Should heparin be included in the PN admixture to reduce the risk of central vein thrombosis?

Recommendation: We suggest that heparin not be included in PN admixtures for reducing the risk of central vein thrombosis in adults. GRADE: Weak



Question 11. What methods of repackaging IVFE into smaller patient-specific volumes are safe?

Recommendation: We recommend against the repackaging of IVFE into syringes for administration to patients. We suggest that other methodologies for repackaged IVFE, such as drawn-down IVFE units, are preferable. *GRADE*: Strong

Automated Compounding device

Ybarra JV, Rose WE, Curtis CS, Sacks GS.

Sterility of pediatric lipid emulsions repackaged by an automated compounding device. *JPEN J*

Parenter Enteral Nutr. 2011;35(3):391-394.







Question 12. What beyond-use date should be used for

- (a)IVFE dispensed for separate infusion in the original container and
- (b) repackaged IVFE.



Question 12. cont'd

Recommendation:


a.We recommend that the beyond-use date (BUD) for unspiked IVFE in the original container should be based on the manufacturer's provided information. The BUD for IVFE in the original container spiked for infusion should be 12–24 hours.

b. Although repackaged IVFE is not recommended, when used, the BUD for IVFE transferred from the original container to another container for infusion separately from a 2-in-1 PN solution should be 12 hours.









Improving Parenteral Nutrition (PN) Safety: Prescribing and Labeling in your Facility



Outline

- Why Focus on PN Safety?
- PN Safety Gap Analysis Survey Results
- Examples of PN Related Errors
- How to Assess our Needs
- Steps to Increase PN Safety
- Action Points



Why Focus on PN Safety?

PN is a

High Alert Medication


one that involves significant risk of harm when used in error

PN is the most complex drug preparation available with 20 – 40 active ingredients

PN use process is interdisciplinary with <u>safety</u> dependent upon individual competance and reliable function of each step



Interdisciplinary PN Process



Boullata J. JPEN J Parenter Enteral Nutr 2012;36:10S-13S



ASPEN PN Practice Surveys

Table 7. Major Findings on Select Safe Practice Issues and Survey Results

Safe Practice Issue	2003 (n = 651), %	2011 (n = 895), %
Organizational systems		
 ≤5 PN admixtures daily 	33	50-82
 Outsourcing of PN compounding 	15	21
 Exclusive use of premixed PN products 	_	2819
Administer outside PN preparations	43	25
Order communication	ines	
 Standardized PN order form 	88	90
 CPOE for PN 	1031	33
 Electronic interface available 	du' - whe	7
 Transcription required 	- net	81
 Ordered in amount/day (or amount/kg/d) 	Vic.	
Macronutrient	19	21-26
Electrolytes	39	11-35
Order review and clarification	100	
 Dedicated pharmacist time = 0 FTEs 	<u> </u>	23
 ≤10% of orders requiring clarification 	61	69
PN compounding		
ACD in use for PN preparations Order transcription to ACD 20 inch	22	64
Order transcription to ACD Equired	84	82
ACD active dose limits in place	_	65
 PN admixture kept refrigerated/out of light 	_	36
Administration		
 Nurse has access to full PN order for review 	_	83
 Policy and procedure for VFE administration 	84	65
Medication errors and door Dentation		
 Performance improvement process 	54	40
 Oversight of PN use process 	_	96
 Aware of PN-related medication errors 	_	34-42
 Document PN order review process in medical record 	_	27-35

ACD, automated compounding device; CPOE, computerized prescriber order entry; FTE, full-time equivalent; IVFE, intravenous fat emulsion; PN, parenteral nutrition. Long dashes represent the lack of data available on certain issues from the 2003 survey.



Parenteral Nutrition Gap Analysis Concerns

- Handwritten PN orders are still very common
 - 62.1% with a standardized order form
 - 5.1% using a non-standardized order form
- 32.7% of organizations use electronic order entry but with only 50% using a standardized process
- 81% of institutions manually transcribe orders
- 23% don't dedicate pharmacist time to review PN orders
- Although 40% have PN performance improvement processes, 44% do not track PN-related medication errors

Frequency and Severity of Harm of Medication Errors Related to PN Process in a Large University Teaching Hospital

- Total of 4730 PN prescriptions
- 74(1.6% of total) associated with medication error
 - 1(1%) Prescription
 - 29 (39%) Transcription
 - 18 (24%) Preparation (Compounding)
 - 26 (35%) Administration
- 67/74 (91%) errors non-harmful to patient
- 6/74(8%) contributed or resulted in temporary patient harm



Summary of Reported PN Errors

Event	Age	Outcome	Contributing factors
Zinc overdose	Neonate	Death	 Performance deficit: training not completed Compounder safeguards not used Dose assessed for appropriateness
Sodium / Calcium	Neonate	Death	 Error in prescription transcription: calcium dose entered as sodium Overlooked at all check points
Glucose overdose	Pediatric	Death	Product label & order misinterpretation
Glucose under dose	Infant	Death	• Final concentration 1.75% vs 17.5%
No dextrose in PN	Neonate	Permanent brain damage	Compounding error
Iron overload	Pediatric	Liver toxicity	Misinterpretation of label, 50 fold error
Hyperkalemia	Child	Death	Manual preparation of PN
Hypermagnesemia	Neonate	Toxicity	Compounder malfunction
Ca/Phosphate precipitate	Adult	Death, respiratory distress	Improper compounding sequence

Adapted from J Mirtallo, A.S.P.E.N. Clinical Nutrition Week 2013



PN Safety Can be Improved in your Institution

What do you do now?



Assess our Needs

- How much PN is used daily, weekly, annually?
- 2. What types of patients receive PN?
- Are PN error reports collected?
- 4. What is the level of PN training of prescribers and pharmacy staff?
- 5. What processes are used to prescribe, communicate orders, verify and create labels?



Assess our Needs

- 1. How much PN is used daily, weekly, annually?
- 2. What types of patients receive PN?
- 3. Are error reports collected?
- 4. What is the level of PN training of prescribers and pharmacy staff?
- 5. What processes are used to prescribe, communicate orders, verify and create labels?



Step 1: Evaluate PN Order Forms

- Why are we suggesting to address this issue?
 - Is easy to do with high potential to improve safety
 - Are able to follow-up to measure and show improvement



A.S.P.E.N. Standardized Prescribing Template for Adult Patients

Patient Information		
Patient nameMedical record	number	Birthdate/age
Patient location	Allergies	
Height and dosing weight: Ht:cm Do	sing Wt:kg	
Diagnosis(es)/Indication(s) for PN		
Vascular access device/location CVC type		Location
Administration date/time		
Base Formula	Amount/day	
Amino acids	g	
Dextrose	g 1	
IV Fat emulsion	g	
Electrolytes		Order in consistent
Sodium phosphate	mmol	Order in consistent
Sodium chloride	mEq	doses per day
Sodium acetate	mEq	doses per day
Potassium phosphate	mmol	
Potassium chloride	mEq	
Potassium acetate	mEq	
Magnesium sulfate	mEq	
Calcium gluconate	mEq	
Vitamins, Trace Elements, Additives		
Multi-component vitamins	mL	
Multi-component Trace elements	mL	
Other Additives (eg, individual vitamins or	trace elements, cystei	ine, regular insulin) as clinically appropriate
and compatible		
PN Instructions		
Total volumemL Infusion rate	mL/hr , start and	stop times
Cycle information		
Prescriber and contact information		

Ayers, et al.,
A.S.P.E.N. Parenteral
Nutrition Safety
Consensus
Recommendations
JPEN J Parenter
Enteral Nutr. 2013

Figure 1. Parenteral Nutrition Order Template: Adult Patient.

A.S.P.E.N. Standardized Prescribing Template for Adult Patients

Patient name	_Medical record number_		Birthdate/age	
			_	-
Height and dosing weight Diagnosis(es)/Indication(s Vascular access device/lo Administration date/time	s) for PN			
Base Formula	An	nount/day		
Amino acids		g		
Dextrose		g		
IV Fat emulsion		g		
Electrolytes				Order should
Sodium phosphate		mmol		L
Sodium chloride		mEq		have same
Sodium acetate		mEq	1	sequence of
Potassium phosphate		mmol		sequence or
Potassium chloride		mEq 🔽		ingredients and
Potassium acetate		mEq		O
Magnesium sulfate		mEq		must match
Calcium gluconate		mEq		la la al
Vitamins, Trace Elements, Add	ditives			label
Multi-component vitamins	3	mL		
Multi-component Trace el	ements	mL		
OH A 1 1111 / 1 11 11	idual vitamins or trace ele	ments, cysteine	, regular insulin) as cl	inically appropriate
Other Additives (eg, indivi				

Ayers, et al.,
A.S.P.E.N. Parenteral
Nutrition Safety
Consensus
Recommendations
JPEN J Parenter
Enteral Nutr. 2013

Figure 1. Parenteral Nutrition Order Template: Adult Patient.

NCE AND
AL NUTRITION
nteral Nutrition

A.S.P.E.N. Standardized Prescribing Template for Pediatric and Neonatal Patients

Patient Information Patient name Medical reco	ord number	Birthdata/aga	
Patient location			
Fatierit location_	Allergies		
Height and dosing weight: Ht:cm	Dosing Wt:kg		
Diagnosis(es)/Indication(s) for PN			
Vascular access device/location CVC t	ype	Location	
Administration date/time			
Base Formula	Amount/kg/day	1	
Amino acids	g		
Dextrose	g		
IV Fat emulsion	g		
Electrolytes		Order in	
Sodium phosphate	mmol	consistant	
Sodium chloride	mEq	consistent	
Sodium acetate	mEq	doses per	
Potassium phosphate	mmol	•	
Potassium chloride	mEq	weight per day	
Potassium acetate	mEq	G	
Magnesium sulfate	mEq		
Calcium gluconate	mEq		
Vitamins, Trace Elements, Additives			
Multi-component vitamins	mL		
Multi-component trace elements	mL		
Other Additives (eg, cysteine, regular ir	nsulin) as clinically approp	oriate and compatible	
PN Instructions			
Total volumemL Infusion rate	emL/hr , start and	stop times	
Cycle information			
Prescriber and contact information			

Figure 2. Parenteral Nutrition Order Template: Pediatric/Neonatal Patient.

Ayers, et al.,
A.S.P.E.N.
Parenteral
Nutrition Safety
Consensus
Recommendations
JPEN J Parenter
Enteral Nutr. 2013

DING THE SCIENCE AND CTICE OF CLINICAL NUTRITION

Parenteral and Enteral Nutrition

A.S.P.E.N. Standardized Prescribing Template for Pediatric and Neonatal Patients

Patient nameMedical reco	ord number	Birthdate/age
Patient location	Allergies	
Height and dosing weight: Ht:cm Diagnosis(es)/Indication(s) for PN Vascular access device/location CVC t Administration date/time		
Base Formula	Amount/kg/day	
Amino acids	g	
Dextrose	g	
IV Fat emulsion	g	
Electrolytes		Order should
Sodium phosphate	mmol	Oraci siloala
Sodium chloride	mEq	have same
Sodium acetate	mEq	f seguence of
Potassium phosphate	mmol	sequence of
Potassium chloride	mEq	ingredients and
Potassium acetate	mEq Y	
Magnesium sulfate	mEq	must match
Calcium gluconate	mEq	label
/itamins, Trace Elements, Additives		labei
Multi-component vitamins	mL	
Multi-component trace elements	mL	and the send account that
Other Additives (eg, cysteine, regular in	nsulin) as clinically appro	priate and compatible
PN Instructions		
Total volumemL Infusion rat	emL/hr , start and	I stop times
Cycle information		
Prescriber and contact information		

Figure 2. Parenteral Nutrition Order Template: Pediatric/Neonatal Patient.

Ayers, et al.,
A.S.P.E.N.
Parenteral
Nutrition Safety
Consensus
Recommendations
JPEN J Parenter
Enteral Nutr. 2013

DING THE SCIENCE AND CTICE OF CLINICAL NUTRITION

Parenteral and Enteral Nutrition

A.S.P.E.N. Adult PN Label

atient Name Medical Reco	rd Number	
rthdate/age		
atlent location		
Height and dosing weight: Ht:cm Dosing Wt:kg		
Diagnosis(es)/Indication(s) for PN		T
Vascular access device/location CVC type	Location	
Administration dateAdministration	n time	•
Macronutrients	Amount/day	
Amino acids*	g	
Dextrose	g	2 7
IV Fat emulsion*	g	
Electrolytes	-	
Sodium phosphate	mmol of phosphate (SodiummEq)	
Sodium chloride	mEg	
Sodium acetate	mEq	
Potassium phosphate	mmol of phosphate (PotassiummEq)	
Potassium chloride	mEq	
Potassium acetate	mEq	
Magnesium sulfate/chloride	mEq	(3)
Calcium gluconate	mEq	
Vitamins, Trace Elements		
Multi-component Vitamins*	mL	•
Multi-component Trace Elements*	mL	
Other Additives (eg, individual vitamins or trace elements, regul	lar Insulin)	
PN Instructions For Central (peripheral) Vein Administration Only		
Total volume mL Overfill volume	ml	
Infusion ratemL/h	- IIIL	
Start and Stop times		1
Cycle Information		4
Do not use after date/time	_	
****** Discard any unused volume after 24 hours*******		
Prescriber and Contact Information		
Institution/Pharmacy Name		
Institution/Pharmacy Address		
Pharmacy Telephone number		

Ayers, et al.,
A.S.P.E.N. Parenteral
Nutrition Safety
Consensus
Recommendations
JPEN J Parenter
Enteral Nutr. 2013

Figure 3. Parenteral Nutrition Label Template: Adult Patient.

*Specify product name.

IG THE SCIENCE AND CE OF CLINICAL NUTRITION

A.S.P.E.N. Adult PN Label



Has Vascular Access Device Tip Location for Nurse to Check



Lists Prescribed Doses Per Day for Nurse to Compare with Order



Lists Prescribed Doses in Standard Sequence for Nurse to Compare with Order



Lists Clear Instructions for Administration



A.S.P.E.N. Pediatric PN Label

Birthdate/age Patient location. Height/Length and dosing weight: Ht/Length:cm Dosing Wt:kg Diagnosis(ee)/Indication(s) for PN	Patient Name	Medical Record Number			
Height/Length and dosing weight: Ht/Length:cm Dosing Wt:kg Diagnosis(es)/Indication(s) for PN	Birthdate/age	_			
Diagnosis(es)Indication(s) for PN_Vascular access device/location CVC type	Patient location				
Diagnosis(es)Indication(s) for PN_Vascular access device/location CVC type					
Vascular access device/location CVC type	Height/Length and dosing weight: Ht/L	ength:cm Dosing Wt:kg			
Administration date					
Macronutrients Amino acids* Q Dextrose IV Fat emulsion* Sodium phosphate Sodium phosphate Sodium chloride Sodium chloride Sodium chloride Fotassium phosphate Potassium phosphate Potassium cetate Potassium chloride Req Req Regnesium sulfate/chloride Req Magnesium sulfate/chloride Calcium gluconate Vitamins, Trace Elements Multi-component Vitamins* Multi-component Trace Elements* Multi-component Trace Elements* Multi-component Trace Elements* Multi-component Trace Elements mL Other Additives Cycteine Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume	Vascular access device/location CVC	typeLocation	1		
Amino acide* Dextrose Dextrose JV Fat emulsion* Electrolytes Sodium phosphate Sodium phosphate Sodium chloride Sodium chloride MEq Modum acetate MEq Potassium phosphate Modum acetate Meq Magnesium sulfate/chloride Meq Magnesium sulfate/chloride Meq Magnesium gluconate Multi-component Vitamins* Multi-component Vitamins* Multi-component Trace Elements* Multi-component Trace Elements* Multi-component Frace Elements* Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume Multi-component	Administration date	Administration Time			
Dextrose IV Fat emulsion* g	Macronutrients	Amount/kg/day b			
Dextrose IV Fat emulsion* Electrolytes Sodium phosphate Sodium phosphate Sodium chloride MEq Sodium castate Potassium chloride Potassium chloride Magnesium sulfate/chloride Calcium gluconate Witamins, Trace Elements Multi-component Vitamins* Multi-component Trace Elements* Multi-component Trace Elements* Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL_Overfill volumemL Infusion rateml_N Start and Stop times Cycle information Do not use after date/time ********************************	Amino acids*	g .			
Electrolytes Sodium phosphate Sodium phosphate Sodium chloride Sodium acetate Potassium phosphate Potassium phosphate Potassium phosphate Potassium chloride Potassium sulfate/chloride Potassium sulfate/chloride REq Magnesium sulfate/chloride Calcium gluconate Witamins, Trace Elements Multi-component Vitamins* Multi-component Trace Elements* Multi-component Trace Elements* Multi-component Trace Elements Multi-component Trace Elemen	Dextrose	_			
Electrolytes Sodium phosphate Sodium phosphate Sodium catate Potassium acetate Potassium phosphate Potassium chloride Potassium chloride Potassium acetate Magnesium sulfate/chloride Calcium gluconate Witamins, Trace Elements Multi-component Vitamins* Multi-component Vitamins* Multi-component Vitamins* Multi-component Vitamins Multi-component Vi	IV Fat emulsion*	_	< 2 >		
Sodium phosphate mmol of phosphate (SodiummEq) Sodium chloride mEq Sodium acetate mEq Potassium phosphate mmol of phosphate (PotassiummEq) Potassium chloride mEq Potassium acetate mEq Magnesium sulftate/chloride mEq Calcium gluconate mEq Vitamins, Trace Elements Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Infusion ratemL/n Start and Stop times Cycle information Do not use after date/time Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Name Institution/Pharmacy Address		•			
Sodium chloride Sodium acetate Sodium acetate Sodium acetate Sodium acetate Sodium acetate Sodium acetate Megassium phosphate Potassium phosphate Potassium chloride Potassium sulfate/chloride Req Magnesium sulfate/chloride Calcium gluconate Witamins, Trace Elements Multi-component Vitamins* Multi-component Trace Elements* Multi-component Trace Elements* Cysteine Cysteine Other Additives Cysteine Other (eg. regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Overfill volumemL Start and Stop times Cycle information Do not use after date/time Discard any unused volume after 24 hours*** Institution/Pharmacy Name Institution/Pharmacy Address	3	mmol of phosphate (Sodium mEq)			
Sodium acetate			•		
Potassium chloride mEq Potassium acetate mEq Magnesium sulfate/chloride mEq Calcium gluconate mEq Vitamins, Trace Elements mL Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time********************************	Sodium acetate	-			
Potassium chloride mEq Potassium acetate mEq Magnesium sulfate/chloride mEq Calcium gluconate mEq Vitamins, Trace Elements mL Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time********************************	Potassium phosphate	mmol of phosphate (Potassium mEg)			
Potassium acetate mEq Magnesium sulfate/chloride mEq Calcium gluconate mEq Vitamins, Trace Elements Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume mL Overfill volume mL Infusion rate mL/h Start and Stop times Cycle information Do not use after date/time ******* Discard any unused volume after 24 hours****** Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address					
Magnesium sulfate/chloride mEq Calcium gluconate mEq Vitamins, Trace Elements Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time ******* Discard any unused volume after 24 hours******* Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address	Potassium acetate	•			
Calcium gluconate mEq Vitamins, Trace Elements Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume mL Overfill volume mL Infusion rate mL/h Start and Stop times Cycle information Do not use after date/time Discard any unused volume after 24 hours***** Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Name Institution/Pharmacy Address	Magnesium sulfate/chloride	•			
Vitamins, Trace Elements Multi-component Vitamins* mL Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume mL Overfill volume mL Infusion rate mL/h Start and Stop times Cycle information Do not use after date/time ******* Discard any unused volume after 24 hours****** Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address		mEa			
Multi-component Trace Elements* mL Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume mL Overfill volume mL Infusion rate mL/h Start and Stop times Cycle information Do not use after date/time ********************************	_				
Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume mL Overfill volume mL Infusion rate mL/h Start and Stop times Cycle information Do not use after date/time ******* Discard any unused volume after 24 hours******* Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address	Multi-component Vitamins*	mL	3		
Other Additives Cysteine mg/g amino acids Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volume mL Overfill volume mL Infusion rate mL/h Start and Stop times Cycle information Do not use after date/time ******* Discard any unused volume after 24 hours******* Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address	Multi-component Trace Elements	* mL			
Others (eg, regular insulin) PN Instructions For Central (peripheral) Vein Administration Only Total volumemL_ Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time *******************************					
PN Instructions For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time ******* Discard any unused volume after 24 hours******* Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address	Cysteine	mg/g amino acids	•		
For Central (peripheral) Vein Administration Only Total volumemL Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time ********************************	Others (eg, regular insulin)				
Total volumemL_ Overfill volumemL Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time ********************************	PN Instructions				
Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time *******************************	For Central (peripheral) Vein Adn	ninistration Only	•		
Infusion ratemL/h Start and Stop times Cycle information Do not use after date/time *******************************	Total volume mL Over	fill volumemL			
Cycle information					
Do not use after date/time ******* Discard any unused volume after 24 hours******* Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address					
Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address					
Prescriber and Contact information Institution/Pharmacy Name Institution/Pharmacy Address					
Institution/Pharmacy Name Institution/Pharmacy Address	****** Discard any unused volume after 24 hours*******				
Institution/Pharmacy Name Institution/Pharmacy Address					
Institution/Pharmacy Address	Prescriber and Contact information	·			
Institution/Pharmacy Address	Institution/Pharmacy Name				
•	-				
Fharmacy Phone Number	Pharmacy Phone Number				

Ayers, et al., A.S.P.E.N. **Parenteral Nutrition** Safety Consensus Recommendations JPEN J Parenter Enteral Nutr. 2013

Figure 4. Parenteral Nutrition Label Template: Pediatric/Neonatal Patient.

*Specify product name.

*Specify product name.

*Since the admixture usually contains multiple sources of sodium, potassium, chloride, acctane, and vided by the PN admixture is determined by adding the amount of electrolyte provided by each salt.

PRACTICE OF CLINICAL NUTRITION

The Parenteral and Enteral Nutrition

A.S.P.E.N. Pediatric PN Label



Has Vascular Access Device Tip Location for Nurse to Check



Lists Prescribed Doses Per Weight Per Day for Nurse to Compare with Order



Lists Prescribed Doses in Standard Sequence for Nurse to Compare with Order



Lists Clear Instructions for Administration



Steps to Increase PN Safety in Our Institution

- Gain buy-in by this P & T Committee
- Adapt A.S.P.E.N. order forms and labels for use in our institution
- Implement monitoring to measure change



Steps to Increase PN Safety in Our Institution

Measure Change:


- Monitor PN errors now for 1-3 months
- In 3-6 months implement new order forms and labels
- In months 6-9 measure PN errors and compare to baseline





Steps to Increase PN Safety in Our Institution


- Future Steps:
- Educate prescribing staff on PN order writing
 - Implement annual PN Order Writing competency program
 - Implement double check policy in pharmacy for order transcription




















Comprehensive Geriatiric Assessment (CGA)


 Integrating Nutrition in the Comprehensive Geriatric Assessment














The young old (65-74 years)
The old (75-84 years)
Oldest old (85-99 years)
Elite old (> 100 years old)



Comprehensive Geriatric Assessment



Comprehensive Geriatric Assessment



Micronutrient Needs of the Elderly

- Vitamin A
- Vitamin B1/Thiamine
- Vitamin B12/Cobalamin
- Vitamin C
- Vitamin D
- Iron
- Zinc





LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION

American Society for Parenteral and Enteral Nutrition

Assessment Questions

- Does education of prescribers improve PN ordering?
- 2. What is the maximum safe osmolarity of PN admixtures intended for peripheral vein administration?
- 3. Is malnutrition associated with hospital readmission in the elderly?







Questions?

